- call +1-201-465-4211
- email sales@mrinsights.biz
According to this study, over the next five years the Opioid-Induced Constipation market will register a 4.8% CAGR in terms of revenue, the global market size will reach $ 2895.4 million by 2025, from $ 2402.9 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Opioid-Induced Constipation business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by type, application, key manufacturers and key regions and countries.
This study considers the Opioid-Induced Constipation value and volume generated from the sales of the following segments:
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Methylnaltrexone Bromide
Lubiprostone
Naloxegol
Others
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmacy
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Takeda Pharmaceuticals
Daiichi Sankyo
Bayer
Mallinckrodt
Salix (Bausch Health)
Sanofi
Purdue Pharm
AstraZeneca
Nektar Therapeutics
Progenics Pharmaceuticals
Prestige
Shionogi
GSK
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Opioid-Induced Constipation consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
Focuses on the key global Opioid-Induced Constipation manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Opioid-Induced Constipation with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Opioid-Induced Constipation submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Opioid-Induced Constipation Consumption 2015-2025
2.1.2 Opioid-Induced Constipation Consumption CAGR by Region
2.2 Opioid-Induced Constipation Segment by Type
2.2.1 Methylnaltrexone Bromide
2.2.2 Lubiprostone
2.2.3 Naloxegol
2.2.4 Others
2.3 Opioid-Induced Constipation Consumption by Type
2.3.1 Global Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2015-2020)
2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2015-2020)
2.4 Opioid-Induced Constipation Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Opioid-Induced Constipation Consumption by Application
2.5.1 Global Opioid-Induced Constipation Consumption Market Share by Type (2015-2020)
2.5.2 Global Opioid-Induced Constipation Value and Market Share by Type (2015-2020)
2.5.3 Global Opioid-Induced Constipation Sale Price by Type (2015-2020)
3 Global Opioid-Induced Constipation by Company
3.1 Global Opioid-Induced Constipation Sales Market Share by Company
3.1.1 Global Opioid-Induced Constipation Sales by Company (2018-2020)
3.1.2 Global Opioid-Induced Constipation Sales Market Share by Company (2018-2020)
3.2 Global Opioid-Induced Constipation Revenue Market Share by Company
3.2.1 Global Opioid-Induced Constipation Revenue by Company (2018-2020)
3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Company (2018-2020)
3.3 Global Opioid-Induced Constipation Sale Price by Company
3.4 Global Opioid-Induced Constipation Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Opioid-Induced Constipation Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Opioid-Induced Constipation Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Opioid-Induced Constipation by Regions
4.1 Opioid-Induced Constipation by Regions
4.2 Americas Opioid-Induced Constipation Consumption Growth
4.3 APAC Opioid-Induced Constipation Consumption Growth
4.4 Europe Opioid-Induced Constipation Consumption Growth
4.5 Middle East & Africa Opioid-Induced Constipation Consumption Growth
5 Americas
5.1 Americas Opioid-Induced Constipation Consumption by Countries
5.1.1 Americas Opioid-Induced Constipation Consumption by Countries (2015-2020)
5.1.2 Americas Opioid-Induced Constipation Value by Countries (2015-2020)
5.2 Americas Opioid-Induced Constipation Consumption by Type
5.3 Americas Opioid-Induced Constipation Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Opioid-Induced Constipation Consumption by Regions
6.1.1 APAC Opioid-Induced Constipation Consumption by Regions (2015-2020)
6.1.2 APAC Opioid-Induced Constipation Value by Regions (2015-2020)
6.2 APAC Opioid-Induced Constipation Consumption by Type
6.3 APAC Opioid-Induced Constipation Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Opioid-Induced Constipation by Countries
7.1.1 Europe Opioid-Induced Constipation Consumption by Countries (2015-2020)
7.1.2 Europe Opioid-Induced Constipation Value by Countries (2015-2020)
7.2 Europe Opioid-Induced Constipation Consumption by Type
7.3 Europe Opioid-Induced Constipation Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Spain
7.10 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Opioid-Induced Constipation by Countries
8.1.1 Middle East & Africa Opioid-Induced Constipation Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Opioid-Induced Constipation Value by Countries (2015-2020)
8.2 Middle East & Africa Opioid-Induced Constipation Consumption by Type
8.3 Middle East & Africa Opioid-Induced Constipation Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Opioid-Induced Constipation Distributors
10.3 Opioid-Induced Constipation Customer
11 Global Opioid-Induced Constipation Market Forecast
11.1 Global Opioid-Induced Constipation Consumption Forecast (2021-2025)
11.2 Global Opioid-Induced Constipation Forecast by Regions
11.2.1 Global Opioid-Induced Constipation Forecast by Regions (2021-2025)
11.2.2 Global Opioid-Induced Constipation Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.5.6 Spain Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Opioid-Induced Constipation Forecast by Type
11.8 Global Opioid-Induced Constipation Forecast by Application
12 Key Players Analysis
12.1 Takeda Pharmaceuticals
12.1.1 Company Information
12.1.2 Opioid-Induced Constipation Product Offered
12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Takeda Pharmaceuticals Latest Developments
12.2 Daiichi Sankyo
12.2.1 Company Information
12.2.2 Opioid-Induced Constipation Product Offered
12.2.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Daiichi Sankyo Latest Developments
12.3 Bayer
12.3.1 Company Information
12.3.2 Opioid-Induced Constipation Product Offered
12.3.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Bayer Latest Developments
12.4 Mallinckrodt
12.4.1 Company Information
12.4.2 Opioid-Induced Constipation Product Offered
12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Mallinckrodt Latest Developments
12.5 Salix (Bausch Health)
12.5.1 Company Information
12.5.2 Opioid-Induced Constipation Product Offered
12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Salix (Bausch Health) Latest Developments
12.6 Sanofi
12.6.1 Company Information
12.6.2 Opioid-Induced Constipation Product Offered
12.6.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Sanofi Latest Developments
12.7 Purdue Pharm
12.7.1 Company Information
12.7.2 Opioid-Induced Constipation Product Offered
12.7.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 Purdue Pharm Latest Developments
12.8 AstraZeneca
12.8.1 Company Information
12.8.2 Opioid-Induced Constipation Product Offered
12.8.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 AstraZeneca Latest Developments
12.9 Nektar Therapeutics
12.9.1 Company Information
12.9.2 Opioid-Induced Constipation Product Offered
12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Nektar Therapeutics Latest Developments
12.10 Progenics Pharmaceuticals
12.10.1 Company Information
12.10.2 Opioid-Induced Constipation Product Offered
12.10.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Progenics Pharmaceuticals Latest Developments
12.11 Prestige
12.11.1 Company Information
12.11.2 Opioid-Induced Constipation Product Offered
12.11.3 Prestige Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Prestige Latest Developments
12.12 Shionogi
12.12.1 Company Information
12.12.2 Opioid-Induced Constipation Product Offered
12.12.3 Shionogi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Shionogi Latest Developments
12.13 GSK
12.13.1 Company Information
12.13.2 Opioid-Induced Constipation Product Offered
12.13.3 GSK Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2018-2020)
12.13.4 Main Business Overview
12.13.5 GSK Latest Developments
13 Research Findings and Conclusion
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Opioid-Induced Constipation Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Pl
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
